Podcast # 419: Etripamil
Dec 20, 2018•4 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Author: Don Stader, MD
Educational Pearls:
- Etripamil is an intranasal calcium channel blocker in development for use in SVT
- A recent study showed that etripamil has an SVT conversion rate of around 80%
- Etripamil does not have the same feeling of "impending doom" that can occur with adenosine
Editor's note: Etripamil is still in development and these results are from a phase II clinical trial.
References:
Stambler BS, Dorian P, Sager PT, Wight D, Douville P, Potvin D, Shamszad P, Haberman RJ, Kuk RS, Lakkireddy DR, Teixeira JM, Bilchick KC, Damle RS, Bernstein RC, Lam WW, O'Neill G, Noseworthy PA, Venkatachalam KL, Coutu B, Mondésert B, Plat F. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31;72(5):489-497. doi: 10.1016/j.jacc.2018.04.082. PubMed PMID: 30049309.
Summarized by Travis Barlock, MS4 | Edited by Erik Verzemnieks, MD
For the best experience, listen in Metacast app for iOS or Android